Natera (NTRA) closed at $399.42 on Oct 19, 2026, up 1.5% on the day. The stock is up 8.1% over the past month, up 49.5% over three months, up 74.4% year to date and up 121.2% over the past year. It trades 8.7% below its 52-week high of $437.41 and 120.7% above its 52-week low of $181.00. The close sits above its 50-day moving average ($359.63) and above its 200-day moving average ($258.35).
NextPick tracks NTRA in its Liquid Biopsy basket alongside GH, GRAL and PSNL. As of Oct 19, 2026, the basket's money-flow score is -20 (weak outflow), and the basket is down 3.2% over five sessions. Over the past month NTRA ranks 2nd of 4 basket members by price change.
Yes — the Oct 19, 2026 close of $399.42 is 54.6% above the 200-day average of $258.35.
NTRA closed 8.7% below its 52-week high of $437.41.
NextPick groups NTRA with GH, GRAL and PSNL in its Liquid Biopsy basket.
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LL
